Opening of Technology Centre

Aortech International PLC
20 September 2000



                     AORTECH  INTERNATIONAL plc
                                  
            Official Opening of AorTech Technology Centre
          by Dr. John Reid, Secretary of State for Scotland

AorTech   International  plc,  the  Scottish-based  manufacturer   of
cardiovascular  devices, announces the opening of its  new  facility,
the  AorTech  Technology Centre, which is adjacent  to  its  existing
premises at the Strathclyde, Business Park, Bellshill.

The new facility will focus on the development of innovative products
and  will  initially  house TruCCOMS, the Continuous  Cardiac  Output
Monitoring  System,  and  the  new  tri-leaflet  heart  valve,  which
utilises Elast-Eon, the new bio-stable material.

The  facility  has  allowed  AorTech to bring  together  the  various
aspects  of the heart valve research, by Glasgow, Leeds and Liverpool
Universities,  under one roof together with AorTech's newly  expanded
development team.
                                  
Eddie McDaid, Managing Director commented:

'The  opening of this Technology Centre represents another  milestone
in  the continued growth and development of AorTech with the focus of
the  Group's  growth based on its exciting innovative products.   The
first  of  these  products, the Continuous Cardiac Output  Monitoring
System (TruCCOMS) represents a major improvement in the monitoring of
patients'  cardiac output both in operating rooms  and  in  intensive
care.

'The  other major innovative product which is in its final stages  of
development  and testing represents the World's first synthetic  tri-
leaflet   heart  valve,  made  from  the  new  bio-stable   Elast-Eon
materials.   This heart valve will revolutionise the  replacement  of
heart  valves throughout the world by introducing a heart valve which
is intended to be as long lasting as mechanical heart valves but with
the added advantage of reduction or elimination of the need for daily
anti-coagulant requirements for patients.

'By securing ownership and rights to these technologies over the last
two  years  the AorTech group has a strong foundation upon  which  to
continue  to build.  We are proud to be at the forefront  of  medical
technology introducing innovative products which will not only have a
major  impact  in  the  global medical device market  but  will  also
enhance  and  improve people's lives.  These new innovative  products
will, I am confident, enable AorTech to become a major global medical
device company in the future'.

Enquiries:                                        20 September 2000

AorTech International plc               01698 746699
Eddie McDaid, Managing Director

College Hill                            020 7457 2020
Michael Padley / Nicholas Nelson

 Copies of this statement will be available for a period of 14 days
                form the Company's registered office:
Phoenix Crescent, Strathclyde Business Park, Bellshill, Scotland ML4 3NU